Nasdaq
$244.00▲ 0.25%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $16.15BShares out 66.2M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
18- 10.16Regular26.10.17 03:586-KKey event#●●●#●●●
Ascendis Pharma A/SBullish
Ascendis Pharma's TransCon CNP (navepegritide) has received a positive opinion from the EMA's CHMP recommending marketing authorization for the treatment of achondroplasia in children. The final decision from the European Commission is expected in Q4 2026, with the initial EU launch under the brand name YUVIWEL planned for Germany in Q1 2027.…more
$244.00+0.25%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.14After-hours26.10.15 06:026-KKey event
Ascendis Pharma A/S
Ascendis Pharma granted a total of 35,890 warrants to certain employees on October 13, 2026. The exercise price for each warrant is set at $223.21 per share, based on the closing price on the date of grant, with a vesting schedule of 25% after one year and the remainder vesting monthly over the following 36 months.…more
$244.00+0.25%vs prev closeView filingShare - 9.29After-hours26.09.30 05:026-KKey event
Ascendis Pharma A/S
Ascendis Pharma issued 210,812 new ordinary shares on September 29, 2026, following the closing of a warrant exercise window. The issuance resulted in an average cash consideration of approximately $123.36 per share, increasing the company's total nominal share capital to 66,400,738 DKK.…more
$244.00+0.25%vs prev closeView filingShare
17 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.17Closed26.10.17 22:52#●●●#●●●
Ascendis Pharma Receives Positive CHMP Opinion for TransCon CNP in Europe…more
Ascendis Pharma announced that the CHMP has issued a positive opinion recommending the approval of TransCon CNP for treating achondroplasia in children. The company expects a final decision from the European Commission in late 2026, with a planned launch in Germany in early 2027.…more
$244.00+0.25%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.16Pre-market26.10.16 21:29
●●●●●●●● ●●●●● ●●●●●●
Ascendis Pharma's TransCon CNP has received a positive opinion from the EMA's CHMP for the treatment of achondroplasia in children. A final decision from the European Commission is expected in Q4 2026, with a planned launch in Germany in Q1 2027.…more
$244.00+0.25%vs prev close - 10.16Pre-market26.10.16 21:31
●●●●●●●● ●●●●● ●●●●●●
Ascendis Pharma's TransCon CNP has received a positive opinion from the EMA's CHMP for the treatment of achondroplasia in children. The final marketing authorization decision from the European Commission is expected in the fourth quarter of 2026.…more
$244.00+0.25%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report